BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 NEW YORK and VANCOUVER, British Columbia

to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

YORK and VANCOUVER, British Columbia, Aug. 23, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell"

or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast

cancer and other cancers, announces it will be present at the H.C. Wainwright 23rd Annual Global Investment Conference (www.hcwevents.com/annualconference).

The conference is being held virtually on September 13-15, 2021.

William Williams, President & CEO of BriaCell, will provide an overview of the Company's business during the presentation.

may listen to the presentation online beginning on September 13 at 7:00 A.M. (ET) via the link below.

H.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)

September 13-15, 2021

Start Date and Time: September 13 at 7:00 A.M. (ET)

Webcasting Link: https://journey.ct.events/view/26971663-6d65-47de-a6f9-30a7a24ba2f0

BriaCell Therapeutics Corp.

is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information

is available at https://briacell.com/.

press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,

other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements

contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"

"could," "estimate," "expect," "intend," "seek," "may," "might,"

"plan," "potential," "predict," "project," "target," "aim," "should,"

"will" "would," or the negative of these words or other similar expressions, although not all forward-looking

statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent

uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions

as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading

"Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks

and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities

and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty

to update such information except as required under applicable law.

TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts

responsibility for the adequacy or accuracy of this release.

H.C. Wainwright & Co.

Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public

and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services

to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in

terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public

equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com.